RecruitingNCT06068257
Tumor-Derived FGF19
Translational Utility of Tumor-Derived FGF19 in a Novel Blood-Based Endocrine Suppression Approach
Sponsor
University of Central Florida
Enrollment
210 participants
Start Date
Jun 6, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw.
- (Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.)
Exclusion Criteria2
- The study will not enroll persons who are unable or unwilling to provide informed consent.
- Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06068257
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
NCT073490692 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226712 locations
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations